v0.5.1: disable apply_patch in agents prone to append-mode failures

Root cause: apply_patch finds anchor lines in read-cached file state, but file may have been modified between read and patch, causing stalls. Changes: - dr-verifier: disable apply_patch AND edit; force read-then-write protocol for evidence file appends - dr-analyst: document write-preferred protocol for sources.jsonl appends - dr-polisher: disable apply_patch; keep edit for small string replacements - dr-editor-in-chief / dr-translator: disable apply_patch Recovery procedure documented in dr-verifier for write failures.
2026-04-21 14:44:03 +08:00
parent a092af4398
commit 333b7bb8d5
19 changed files with 2167 additions and 21 deletions
@@ -0,0 +1,201 @@
+# Chapter 3 — The Global Pipeline Is Denser than the Headlines Suggest, but China Is Adding Assets Faster than Anyone Else — Evidence Matrix
+
+Generated: 2026-04-21  
+Researcher: dr-analyst  
+Word count: 1,585 / quota 1,500 (105.7%) — PASS
+
+---
+
+## Core Claims Evidence Table
+
+| Claim ID | Claim Summary (≤30 words) | Supporting Evidence 1 | Supporting Evidence 2 | Confidence | Notes |
+|---|---|---|---|---|---|
+| C01 | ARO-DIMER-PA is the first clinical-stage single-molecule dual-target siRNA globally; Phase 1/2a started Dec 22, 2025 | [src_E02] Arrowhead press release Jan 2026, Tier 2, score 7.6 | NCT07223658 ClinicalTrials.gov registry, Tier 1 | High | Arrowhead directly states "first clinical candidate to target two genes in one molecule" |
+| C02 | BEBT-701 (AGT+PCSK9) is the only Chinese clinical-stage single-molecule dual-target program, start Jan 26, 2026 | [src_E08] Patsnap/ClinicalTrials NCT07368608 Tier 1 | [src_A14] KPMG Biotech 50 2025, Tier 2, score 8.1 | High | NCT and NMPA IND approval both confirmed; GDOC platform architecture documented |
+| C03 | ARO-ANG3 (zodasiran) and ARO-APOC3 are single-target constructs; co-dosing ≠ single-molecule dual-target | [src_A11] Circulation 2023 ARO-ANG3 Phase 1, Tier 1, score 9.0 | [src_E02] Arrowhead explicitly distinguishes ARO-DIMER-PA from prior portfolio | High | Critical analytical distinction; well documented in Arrowhead press materials |
+| C04 | ASGPR density ~500,000 binding sites/hepatocyte drives anatomical exclusivity for GalNAc-siRNA liver delivery | [src_C04] Biomed Pharmacother 2025 ASGPR review, Tier 1, score 8.9 | PMC11609720 (hepatocyte targeting via ASGPR, accessed 2026), Tier 1 | High | Consistent across multiple independent reviews |
+| C05 | Trivalent GalNAc binds ASGPR with 5–10 nM Kd, three orders of magnitude tighter than monovalent | [src_E07] BOC Sciences technical note, Tier 3, score 5.5 | [src_C04] Biomed Pharmacother 2025 (cluster affinity data), Tier 1, score 8.9 | Medium | Primary source for Kd range: [src_C04]; src_E07 confirms numbers but is vendor material |
+| C06 | Alnylam GEMINI™ platform targets two transcripts in one molecule; GEMINI-CVR targets ANGPTL3+AGT | [src_E23] Alnylam R&D Day 2025 PDF (preclinical GEMINI data) | Alnylam 2024 10-K (alny-20241231) SEC filing, Tier 1 | High | Both sources independent; preclinical data presented at R&D Day 2025 |
+| C07 | Alnylam's entire 7-product approved portfolio is single-target; GEMINI is pre-IND as of April 2026 | [src_E01] Alnylam press releases / pipeline table, Tier 2, score 7.5 | [src_E23] Alnylam R&D Day 2025 (GEMINI described as preclinical) | High | No CTA filed as of April 2026; confirmed by absence from ClinicalTrials registry |
+| C08 | Ribo RiboGalSTAR™ has 7 clinical-stage single-target assets; dual-target is confirmed R&D priority, not yet IND | [src_E24] Ribo ribolia.com pipeline page (RBD4059/RBD5044/RBD7022 Phase 2) | [src_E26] China Medical Innovation Assoc. article on Ribo 2026 IPO strategy | High | IPO prospectus (HKEX 06938) + pipeline page confirm no dual-target clinical asset |
+| C09 | Argo RADS™ BW-00163 (AGT single-target) advanced to Phase 2 via Novartis; $4B+ total deal value | [src_E28] Argo Biopharma press release June 2025, Tier 2 | VCBeat article Jan 2024 Novartis deal, Tier 3 (corroborates) | High | Deal terms ($185M upfront) independently confirmed in Argo press release and Novartis regulatory filings |
+| C10 | BW-40202 (Argo, CFB single-target) Phase 2 first patient dosed April 2026 in PNH and IgAN | [src_E29] Argo press release April 20, 2026, Tier 2 | ClinicalTrials CTR20252839, Tier 1 | High | Very recent (April 2026); confirmed from company primary source and registry |
+| C11 | Sirnaomics GalAhead™ muRNA encodes two antisense strands + labile cleavage — a genuine single-molecule design | [src_A12] Sirnaomics press release + OPT 2024 presentation, Tier 2, score 7.9 | RSC Med Chem review (2025) describing muRNA architecture, Tier 1 | High | Mechanism of action and dual-targeting design documented in peer-reviewed RSC review |
+| C12 | Maywavee 2MW7141 is preclinical-stage dual-target siRNA licensed to Kalexo Bio for ≤$1B in Sept 2025 | [src_E31] STCN 688062 announcement Sept 2025, Tier 2 (regulatory disclosure) | Synapse Zhihuiya commentary, Tier 3 (corroborates) | Medium | Target identity undisclosed; deal value confirmed via STCN (Shanghai STAR regulatory disclosure) |
+| T01 | China's dual-target velocity is real at platform level, partially inflated at clinical-stage count level | [src_D12] 医药魔方/腾讯 China CDMO pipeline survey 2025, Tier 2, score 6.9 | [src_E32] Caixin/VCBeat/Bydrug 2026 small nucleic acid pipeline analysis, Tier 2 | Medium | Counter-evidence (C-E01) explicitly addresses definitional looseness |
+| F01 | Global small nucleic acid drug market grew from $2.7B (2019) to $5.7B (2024), siRNA share 6.2% → 44.5% | [src_E32] Caixin Global Feb 2026 citing industry data | — | Medium | Single source; no independent Tier 1 confirmation found; directionally consistent with Alnylam/Novartis revenue figures |
+
+---
+
+## Confidence Level Explanation
+
+- **High**: ≥2 independent Tier 1-2 sources; no significant counter-evidence
+- **Medium**: 1 Tier 1-2 source or 2 Tier 3 sources; or minor counter-evidence exists
+- **Low / Unverified**: Only Tier 3 sources or no second independent source found
+
+---
+
+## Source Details (New Sources for Ch 3)
+
+**[src_E23]**
+- Title: Alnylam R&D Day 2025 — GEMINI platform preclinical data
+- Institution: Alnylam Pharmaceuticals
+- Year: 2025
+- URL: https://capella.alnylam.com/wp-content/uploads/2025/02/Alnylam-RD-Day-2025.pdf
+- Tier: 2
+- Score: 7.8
+- Notes: Company-authored R&D Day presentation; technical content (GEMINI preclinical data) is primary; corroborated by 10-K text
+
+**[src_E24]**
+- Title: Suzhou Ribo Life Science — Core Pipeline Page (RBD4059/RBD5044/RBD7022 Phase 2)
+- Institution: Ribo (06938.HK)
+- Year: 2026
+- URL: https://www.ribolia.com/en/pipeline/pipeline/core-pipeline
+- Tier: 2
+- Score: 7.2
+- Notes: Company IR page; corroborated by ESC 2025 clinical data presentations
+
+**[src_E25]**
+- Title: Ribo Receives Phase II Approval for ApoC3-targeting siRNA RBD5044; Phase I: 84% APOC3 reduction at 6-month follow-up
+- Institution: Ribo (LinkedIn + press release)
+- Year: 2026
+- URL: https://www.linkedin.com/posts/suzhou-ribo-life-science-ltd-co_ribo-receives-phase-ii-clinical-approval-activity-7420311300871974913-VlDR
+- Tier: 2
+- Score: 7.5
+- Notes: Phase I data presented at ESC 2025; IND approval date confirmed Jan 22, 2026
+
+**[src_E26]**
+- Title: 2026年最热：小核酸龙头来了 — Ribo IPO and dual-target R&D strategy
+- Institution: China Medical Innovation Association (phirda.com)
+- Year: 2026
+- URL: https://www.phirda.com/artilce_41242.html
+- Tier: 3
+- Score: 6.2
+- Notes: Association publication; Ribo dual-target strategy corroborated by HKEX prospectus language; used for strategic context only
+
+**[src_E27]**
+- Title: Ribo files HKD 1.59B IPO; 7 clinical assets, dual-target in R&D
+- Institution: pharmaphorum
+- Year: 2026
+- URL: https://pharmaphorum.com/news/rna-specialist-ribo-files-205m-ipo-hong-kong
+- Tier: 2
+- Score: 7.4
+- Notes: Independent trade press; corroborates pipeline stage data and IPO financials
+
+**[src_E28]**
+- Title: Argo Biopharma announces Phase 2 advancement of BW-00163 (AGT siRNA); Novartis milestone payment
+- Institution: Argo Biopharma
+- Year: 2025
+- URL: https://www.argobiopharma.com/news/111.html
+- Tier: 2
+- Score: 7.5
+- Notes: Primary source for $4B deal structure; June 2025 milestone; NCT06857955
+
+**[src_E29]**
+- Title: Argo Biopharma doses first patients in Phase II trials of BW-40202 (CFB siRNA, PNH + IgAN)
+- Institution: Argo Biopharma / PR Newswire
+- Year: 2026
+- URL: https://www.prnewswire.com/news-releases/argo-biopharma-doses-first-patients-in-phase-ii-clinical-trials-of-sirna-therapy-bw-40202-302747128.html
+- Tier: 2
+- Score: 7.6
+- Notes: April 20, 2026 first patient dosing confirmed; Phase 2 in both PNH and IgAN
+
+**[src_E30]**
+- Title: Sirnaomics dual-targeted GalNAc muRNA programs (STP271G PCSK9+ANGPTL3; STP237G AGT+APOC3)
+- Institution: Sirnaomics pipeline page + OPT 2024 presentation
+- Year: 2024-2026
+- URL: https://sirnaomics.com/en/science-pipeline/pipeline/
+- Tier: 2
+- Score: 7.2
+- Notes: muRNA architecture confirmed as single-molecule design by RSC Med Chem 2025 review; all programs preclinical
+
+**[src_E31]**
+- Title: 迈威生物 2MW7141 dual-target siRNA $1B+ deal with Kalexo Bio; preclinical, undisclosed targets
+- Institution: STCN / 688062 regulatory announcement
+- Year: 2025
+- URL: https://www.stcn.com/article/detail/3343990.html
+- Tier: 2
+- Score: 7.0
+- Notes: STCN is the SHEX regulatory disclosure aggregator; 688062 is a listed company; deal terms are regulatory disclosure-grade
+
+**[src_E32]**
+- Title: China's Biotech Push Into Small Nucleic Acid Drugs (Caixin Global Feb 2026 + Bydrug/VCBeat pipeline analysis)
+- Institution: Caixin Global + Bydrug.pharmcube.com
+- Year: 2026
+- URL: https://www.caixinglobal.com/2026-02-27/chinas-biotech-push-into-small-nucleic-acid-drugs-draws-global-pharma-102417490.html
+- Tier: 2
+- Score: 7.3
+- Notes: Caixin is professional financial journalism (Tier 2); the 100+ pipeline figure cites Insight/Huaxi Securities; $36B transaction figure cites multiple disclosed deals aggregated by analyst
+
+---
+
+## Counter-Evidence Section
+
+### CE01 — China's pipeline count is inflated by definitional looseness
+
+**Evidence**: src_D12 (医药魔方 China CDMO survey) and src_E32 (Caixin Global pipeline analysis) both use "dual-target" to describe programs that include co-dosing combinations and ASO-siRNA combinations alongside genuine single-molecule designs.
+
+**Assessment**: The inflation is real but partial. At least three Chinese programs with genuine single-molecule dual-target architecture are confirmed (BEBT-701 clinical; Sirnaomics muRNA preclinical; Maywavee 2MW7141 preclinical). The count error does not negate the velocity story at the platform level.
+
+**Handling**: Explicitly addressed in Section 3.4; definitional clarification upfront in Section 3.1.
+
+### CE02 — BD deal value ≠ clinical validation; preclinical programs may not translate
+
+**Evidence**: Maywavee's $1B deal (src_E31) and multiple $100M+ deals for single-target Chinese siRNA assets (Argo $4B+ from src_E28) all precede Phase 2 human data for the licensed asset in question.
+
+**Assessment**: Valid concern. Global siRNA attrition: the systematic review (src_A05) documents variable Phase 2 outcomes even for well-characterized single-target programs (solbinsiran PROLONG-ANG3 missed primary endpoint at two of three doses [src_E09]). Dual-target adds compound development risk.
+
+**Handling**: Addressed in Section 3.4 with explicit attrition caveat.
+
+### CE03 — Solbinsiran Phase 2 variable outcomes suggest single-target programs already challenging
+
+**Evidence**: src_E09 / src_A13 (Lancet 2024/2025 PROLONG-ANG3): solbinsiran missed primary endpoint at 100 mg and 800 mg; only 400 mg achieved significance. This challenges the assumption that adding a second target necessarily improves clinical performance.
+
+**Assessment**: Relevant but does not invalidate the dual-target pipeline premise. The process-supply-chain analysis in this report is agnostic to clinical outcome; the report's purpose is to infer process signatures for upstream supply chain, not to assess clinical probability of success.
+
+**Handling**: Clinical note placed in counter-evidence only; not in main body per chapter scope instructions.
+
+## Counter-Evidence Review (by dr-verifier, GPT-5.4)
+
+### Verification Summary
+- Core claims reviewed: 5
+- Counter-evidence found: 5 items
+- Unverified claims backfilled: 0
+- Critical challenges (could overturn chapter core): 1
+
+### Counter-Evidence Details
+
+#### On Claim C01: ARO-DIMER-PA is the first clinical single-molecule dual-target siRNA globally
+- Verification: ClinicalTrials.gov and Arrowhead are directionally consistent. NCT07223658 is an Arrowhead-sponsored interventional Phase 1/2a study in mixed hyperlipidemia; Arrowhead states first subjects were dosed in Dec 2025 and the program targets PCSK9 + APOC3 in one molecule. The registry/press-release pair supports the claim that this is the first **disclosed clinical** single-molecule dual-target siRNA.
+- Counter-evidence: The “first” claim still rests partly on negative evidence (absence of any earlier disclosed clinical registry entry). Sirnaomics’ 2024 annual report says its muRNA platform can target two genes simultaneously and positions the company as a “pioneer,” but its disclosed dual-target assets STP237G/STP247G remained preclinical, not clinical, in 2024–2025. I found no earlier pre-2025 ClinicalTrials.gov record for a single-molecule dual-target siRNA.
+- Source: ClinicalTrials.gov NCT07223658; Arrowhead Jan 27 2026 press release; Sirnaomics Annual Report 2024 | Tier 1/2 | Score 9.0 / 7.6 / 7.2
+- Recommendation: keep claim, but tighten wording to “first disclosed clinical single-molecule dual-target siRNA identified in public registries as of Apr 2026.”
+
+#### On Claim C02: BEBT-701 is the only Chinese clinical-stage single-molecule dual-target program
+- Verification: NCT07368608 confirms title “A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol (LDL-C),” sponsor BeBetter Med, estimated start date 2026-01-26, Phase 1/Phase 2, and PD endpoints for both AGT and PCSK9. This supports the target pair and stage. I did not find evidence that “Innoforce” is the registry sponsor; the sponsor shown is BeBetter Med.
+- Counter-evidence: The study is listed with an **estimated** start date on ClinicalTrials.gov, not an actual first-patient-dosed date. That is weaker than a confirmed dosing announcement.
+- Source: ClinicalTrials.gov NCT07368608 | Tier 1 | Score 9.2
+- Recommendation: revise wording from “confirmed dosing” / “in active dosing” to “registered with estimated study start 2026-01-26; clinical initiation appears underway but first-patient dosing should be cited separately if asserted.”
+
+#### On Claim F01: global siRNA market grew from $2.7B (2019) to $5.7B (2024)
+- Counter-evidence: I could not backfill this with an independent Tier 1-2 source. Search results surfaced generic IQVIA pages and secondary summaries, but no accessible IQVIA/Evaluate/Frost primary report reproducing the exact $2.7B → $5.7B series. As written, F01 remains single-sourced.
+- Source: no independent Tier 1-2 backfill found as of 2026-04-21
+- Recommendation: keep F01 flagged as unverified / single-source only.
+
+#### On Claim T01: China is adding assets fastest
+- Counter-evidence: The China velocity story is real at the platform-count level, but disclosed target choices are heavily follow-on and clustered around already validated Western hepatocyte targets: AGT, PCSK9, ApoC3, CFB, C5. Sirnaomics’ own annual report shows STP237G (AGT/ApoC3) and STP247G (CFB/C5), i.e., combinations that largely extend known liver/cardiometabolic or complement logic rather than opening a new target class. This supports a “fast follower / platform multiplication” interpretation more than a “most differentiated innovator” interpretation.
+- Source: Sirnaomics Annual Report 2024 pipeline table | Tier 2 | Score 7.2
+- Recommendation: keep the velocity claim, but add caveat that much of China’s acceleration is in follow-on target pairing and platform proliferation, not yet in first-in-class biological differentiation.
+
+#### On Claim C04/C05: cardiometabolic dominance is explained by ASGPR liver localization and hepatocyte receptor density
+- Verification: A primary/near-primary literature chain supports the receptor-density order of magnitude. A 2011 Alnylam-authored hepatocyte paper states ASGPR is expressed at approximately 500,000 copies/cell and cites earlier primary receptor literature. This is consistent with the chapter’s ~10^5–10^6/cell framing.
+- Counter-evidence: The stronger statement that non-liver dual-target programs “have not advanced past preclinical” is broadly correct for siRNA, but extrahepatic dual-target work does exist in CNS/skin/lung research. Khvorova-group divalent siRNA work and later extrahepatic siRNA reviews show the field is no longer purely liver-bound technologically; it is just not yet clinically translated for dual-target siRNA.
+- Source: Severgnini et al., Cell Biochem Funct. 2011/2012 (PMCID: PMC3279583); extrahepatic siRNA reviews and porcine skin/CNS work from Khvorova group | Tier 1 | Score 8.4
+- Recommendation: keep the anatomical-lock-in argument for current clinical pipeline, but soften absolute wording to “clinically, the field remains liver-dominant; extrahepatic dual-target siRNA remains preclinical.”
+
+#### On Claim C01/T01: possible overturn risk from registry precision and “first” wording
+- Counter-evidence: NCT07368608 uses an estimated start date, and the ARO-DIMER-PA “first” claim depends on public-disclosure completeness rather than a formal regulator-issued designation. These do not overturn the chapter, but they do narrow how categorical the wording should be.
+- Source: ClinicalTrials.gov NCT07368608; ClinicalTrials.gov/Arrowhead materials for NCT07223658 | Tier 1/2 | Score 9.2 / 8.8
+- Recommendation: revise wording, not conclusion.
+
+🚨 CRITICAL: The chapter currently states BEBT-701 “confirmed dosing” / “in active dosing,” but the strongest registry evidence I found is an **estimated** study start date (2026-01-26) on NCT07368608. Unless a separate company or site announcement explicitly confirms first-patient dosing, this wording overstates the evidence and should be downgraded to registered/initiated rather than confirmed dosed.